Browsing Tag
Hims & Hers Health
8 posts
From Eli Lilly to Hims & Hers: what Kathryn Beiser’s move says about the telehealth platform’s ambitions
Hims & Hers Health appoints Kathryn Beiser as Chief Communications Officer. Explore what the move signals about strategy, growth, and investor sentiment.
HIMS near 52-week low as FDA issues 30 GLP-1 warning letters
FDA sends 30 warning letters to GLP-1 compounders, targeting Hims & Hers Health (HIMS) as regulatory and legal pressure intensifies. Read what it means for investors and the sector.
Why Hims & Hers Health’s decision to offer Grail’s Galleri test looks riskier after the U.K. NHS trial miss
Grail’s Galleri cancer test missed a major U.K. NHS trial goal just as Hims & Hers Health began offering it. Find out what this means for investors and screening strategy.
Hims & Hers Health plunges 11% after CEO Andrew Dudum offloads $11m in stock
Shares of Hims & Hers Health fell 11% after CEO Andrew Dudum disclosed a multimillion-dollar stock sale. Find out what’s worrying investors next.
Why Hims & Hers Health’s new COO appointment matters as FDA scrutiny and growth collide
Hims & Hers Health (NASDAQ: HIMS) promotes Mike Chi to COO, consolidating leadership as it faces growth, regulation, and investor scrutiny in telehealth.
Wall Street hit by broad-based sell-off as renewable, healthcare, and tech stocks tumble
Renewable energy, healthcare, and tech stocks led losses in the U.S. stock market on May 22, 2025. Explore what triggered the sell-off and what’s next.
Hims & Hers Health soars over 10% after Wegovy rollout, Q1 strength, and analyst upgrades
Hims & Hers Health stock jumped 10.36% on May 16, 2025, after a Wegovy rollout, strong Q1 earnings, and analyst upgrades boosted investor confidence.
Snap, First Solar, Reddit among biggest losers as broad selloff hits U.S. markets
Discover why U.S. stocks like Snap, Evolution AB, and Super Micro plunged amid recession fears, tariff disruptions, and earnings-driven volatility.